Research programs
in cancer supportive care
TL-01 leads our portfolio of eight research programs in cancer supportive care.
Research & development portfolio
The portfolio includes serotonergic and non-serotonergic approaches at different stages of discovery and lead optimization.
| Program | Research focus | Stage reached |
|---|---|---|
| TL-01Lead program | Lead neuroplastogen We are developing TL-01 for cancer-related cognitive impairment, with the goal of an oral medicine suitable for oncology care. | Lead optimizationPreclinical research |
| TL-02 | Dual-action prodrug research Chimeric compounds are being studied as dual-action prodrugs. | Hits synthesizedDiscovery |
| TL-03 | Neuroinflammation research The research examines inflammatory biology and its relevance to cognitive function. | Hits synthesizedDiscovery |
| TL-04 | Short-acting CNS program We are investigating compounds designed for a shorter duration of action. | Hit identificationEarly discovery |
| TL-05 | Neuroplastogen discovery We are exploring novel neuroplastogen chemistry for cancer supportive care. | Hit identificationEarly discovery |
| TL-06 | Cognition-focused research The research examines serotonergic approaches to cognitive function. | Hit identificationEarly discovery |
| TL-07 | HDAC6-targeted research This program investigates a non-serotonergic approach to cognition and neuropathy. | Hit identificationEarly discovery |
| TL-08 | TrkB-targeted research This program explores neurotrophic signaling through a non-serotonergic approach. | DiscoveryPre-candidate research |
Each marker identifies the current research stage. The markers do not quantify completion or forecast future progress. All programs remain in discovery or preclinical research and none is in clinical development.
The descriptions summarize the aims of each research program. Therapeutic effects, safety and effectiveness have not been established.
Evaluating each program
Our development plans cover chemistry, pharmacology, safety, neural plasticity and disease-relevant outcomes.
TL-01 is our lead development priority. We are also exploring complementary biological approaches across the portfolio and will assess each program on its own evidence. Contact us for further information about our programs.
Contact our team